Boston Scientific Corporation's (NYSE:BSX) Chairman, President, and CEO, Michael F. Mahoney, has sold a substantial portion of his stock in the company, according to a recent SEC filing. The transactions, which took place on October 7, involved the sale of 162,777 shares for a total value exceeding $13.7 million, with individual sale prices ranging from $84.31 to $84.94.
The same filing also reported that Mahoney acquired a total of 111,886 shares through stock option exercises, valued at approximately $1.88 million, with prices between $16.31 and $17.26. It is important to note that these transactions were conducted under a pre-established trading plan known as Rule 10b5-1, which allows company insiders to set up a schedule for buying and selling stock at a time when they are not in possession of material non-public information.
Investors often keep a close eye on insider transactions as they can provide insights into the executives' perspectives on the company's current valuation and future prospects. The sale by Mahoney represents a significant transaction by a key executive at Boston Scientific, a leading manufacturer of medical devices used in interventional medical specialties.
Boston Scientific has not made any official statement regarding the transactions, and it remains common practice for executives to diversify their investment portfolios through planned stock sales. The company continues to perform in the market, with the stock price reflecting investor confidence in its growth and strategic direction.
For those interested in the detailed figures, the SEC filing is publicly available and provides full disclosure of the transactions, including the number of shares sold at each separate price upon request.
As of the latest report, following these transactions, Mahoney still holds a significant number of shares in Boston Scientific, both directly and indirectly, indicating a continued vested interest in the company's performance.
In other recent news, Boston Scientific has experienced a series of significant developments. TD Cowen reiterated its Buy rating on Boston Scientific, expressing confidence in the upcoming Acurate IDE trial results. The firm anticipates these results could support the Acurate device's approval in the United States, potentially in the first half of 2025.
Boston Scientific has also recently completed its acquisition of Silk Road Medical (NASDAQ:SILK), adding the innovative transcarotid artery revascularization procedure to its portfolio. Furthermore, Boston Scientific received approval from Japan's Pharmaceuticals and Medical Device Agency for its FARAPULSE Pulsed Field Ablation System, with plans to launch the system in Japan shortly.
The company has also reported substantial increases in revenue and adjusted earnings per share for the second quarter, exceeding expectations. Analyst firms BofA Securities, Piper Sandler, and TD Cowen have all maintained positive ratings on Boston Scientific's shares, reflecting confidence in the company's growth trajectory.
Lastly, the U.S. Food and Drug Administration has approved the expansion of the use of Boston Scientific's INGEVITY+ Pacing Leads for conduction system pacing and sensing in the left bundle branch area. These recent developments highlight Boston Scientific's ongoing commitment to innovation and growth.
InvestingPro Insights
To provide additional context to Michael F. Mahoney's recent stock transactions, let's examine some key financial metrics and insights from InvestingPro for Boston Scientific Corporation (BSX).
As of the latest data, Boston Scientific boasts a substantial market capitalization of $126.5 billion, underscoring its position as a major player in the Healthcare Equipment & Supplies industry. This aligns with the InvestingPro Tip highlighting BSX as a "prominent player" in its sector.
The company's revenue growth is noteworthy, with a 13.65% increase over the last twelve months as of Q2 2024, and an even stronger 14.48% growth in the most recent quarter. This robust top-line performance supports the InvestingPro Tip suggesting that "net income is expected to grow this year."
Despite the significant stock sale by CEO Mahoney, BSX's stock price remains near its 52-week high, with a price that is 99.71% of its peak. This strength is reflected in the impressive one-year price total return of 61.95%, indicating sustained investor confidence in the company's trajectory.
It's worth noting that while BSX trades at a high P/E ratio of 68.64, the PEG ratio of 0.65 suggests that the stock may be undervalued relative to its growth prospects. This aligns with the InvestingPro Tip stating that BSX is "trading at a low P/E ratio relative to near-term earnings growth."
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for Boston Scientific, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.